Virtus Biotech Clinical TriaBBCETF
13F holders, Q4 2024 (December 31)9holders −4
1new positions
5sold out
$23.94avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Virtus Biotech Clinical Tria (BBC) in their 13F filings, down 4 from Q3 2024. 1 opened new positions and 5 sold out. The largest holders were Susquehanna International Group, LLP ($1.0M), LPL Financial LLC ($312K) and Morgan Stanley ($275K).
- Company
- Virtus Biotech Clinical Tria
- Filed as
- ETFIS SER TR I (Q4 2024)
- CUSIP
- 26923G301
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $4K |
| Exits | 5 | $1.0M |
All 13F filers, Q3 2024 → Q4 2024: 394 shares bought and 40,383 shares sold, net −39,989 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Susquehanna International Group, LLP | 0.00% | Reduce -5.2% | 43,735 | $1.0M |
| LPL Financial LLC | 0.00% | Add +1.8% | 13,039 | $312K |
| Morgan Stanley | 0.00% | Reduce -12.6% | 11,497 | $275K |
| US Bancorp \de | 0.00% | No change | 1,000 | $24K |
| Osaic Holdings, Inc. | 0.00% | No change | 447 | $11K |
| Federation des caisses Desjardins du Quebec | 0.00% | Reduce -64.9% | 294 | $7K |
| UBS Group AG | 0.00% | New | 168 | $4K |
| Allworth Financial LP | 0.00% | No change | 10 | $229 |
| NewEdge Advisors, LLC | 0.00% | No change | 5 | $120 |
"% of holder's portfolio" is BBC's weight in each manager's 13F, not the share of Virtus Biotech Clinical Tria the manager owns.